1-7 of 7
Laurence Gamelin
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Updated Efficacy and Safety of Tabelecleucel in Patients with Epstein-Barr Virus-Positive (EBV + ) Leiomyosarcomas (LMS)

Lauren S Jiménez-Kurlander, Gerald Behr, Nancy J Bunin, Ekaterina Doubrovina, Rajani Dinavahi, Laurence Gamelin, Armin Ghobadi, Leo Mascarenhas, Sarah Nikiforow, Richard J O'Reilly, Anita Price, Barry Shulkin, Ashok Srinivasan, Stephanie Suser, Justin Wahlstrom, Baodong Xing, Susan Prockop
Journal: Blood
Blood (2022) 140 (Supplement 1): 7524–7526.
https://doi.org/10.1182/blood-2022-157765
Published: 2022
Journal Articles

Exploring the Impact of Humoral Immunogenicity with Tabelecleucel for the Treatment of EBV + PTLD Following HCT and SOT

Tassja J Spindler, Fiona Ruiz, Tiffany Jehng, Hanna Ding, Norma Guzman-Becerra, Shahram Khanzadeh, Xiaoming Li, Laurence Gamelin, Jason A. Dubovsky, Cokey Nguyen
Journal: Blood
Blood (2022) 140 (Supplement 1): 7529–7530.
https://doi.org/10.1182/blood-2022-157673
Published: 2022
Journal Articles

New and Updated Results from a Multicenter, Open-Label, Global Phase 3 Study of Tabelecleucel (Tab-cel) for Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV + PTLD) Following Allogeneic Hematopoietic Cell (HCT) or Solid Organ Transplant (SOT) after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)

Kris Michael Mahadeo, Robert A. Baiocchi, Amer Beitinjaneh, Sridhar Chaganti, Sylvain Choquet, Daan Dierickx, Rajani Dinavahi, Laurence Gamelin, Armin Ghobadi, Norma Guzman-Becerra, Manher Joshi, Aditi Mehta, Sarah Nikiforow, Ran Reshef, Wei Ye, Susan Prockop
Journal: Blood
Blood (2022) 140 (Supplement 1): 10374–10376.
https://doi.org/10.1182/blood-2022-157766
Published: 2022
Journal Articles

Overall Survival By Best Overall Response with Tabelecleucel in Patients with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease Following Solid Organ or Allogeneic Hematopoietic Cell Transplant

Susan Prockop, Laurence Gamelin, Rajani Dinavahi, Yan Sun, Weizhi Zhao, Faith Galderisi, Aditi Mehta
Journal: Blood
Blood (2021) 138 (Supplement 1): 887.
https://doi.org/10.1182/blood-2021-147226
Published: 2021
Journal Articles

Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Recipients with Epstein-Barr Virus-Driven Post Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)

Susan Prockop, Kris Michael Mahadeo, Amer Beitinjaneh, Sylvain Choquet, Patrick Stiff, Ran Reshef, Gowri Satyanarayana, Saurabh Dahiya, Hema Parmar, Wei Ye, Laurence Gamelin, Rajani Dinavahi
Journal: Blood
Blood (2021) 138 (Supplement 1): 301.
https://doi.org/10.1182/blood-2021-147274
Published: 2021
Journal Articles

A Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ Transplant Subjects with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease (EBV + PTLD) after Failure of Rituximab or Rituximab and Chemotherapy

Susan Prockop, MD, Minoti Hiremath, MBBS, PhD, Wei Ye, PhD, Laurence Gamelin, MD, Willis Navarro, MD, Kris Michael Mahadeo, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5326.
https://doi.org/10.1182/blood-2019-129277
Published: 2019
Journal Articles

A Systematic Literature Review and Meta-Analysis of the Risk of Thromboembolic Events in Patients with Immune Thrombocytopenia (ITP) in Observational Studies.

Wendy Langeberg, PhD, MPH, Melissa Eisen, MD, W. Marieke Schoonen, PhD, MPH, Laurence Gamelin, MD, PhD, Scott Stryker, MD, DrPH
Journal: Blood
Blood (2012) 120 (21): 2187.
https://doi.org/10.1182/blood.V120.21.2187.2187
Published: 2012